Inhibitor compounds of Bcr-Abl and Bcr-Abl mutants including Bcr-Abl T315I mutant protein are disclosed. Compositions comprising the inhibitor compounds and methods of using the compounds in the treatment of leukemia such as chronic myelogenous leukemia are also disclosed.